STRC DFNB16 Therapeutic Window — Iranfar 2026
The Iranfar 2026 mouse study is the clearest quantitative statement of the STRC treatment window. It defines when AAV delivery works, when it doesn’t, and why human translation is not straightforward.
Mouse data
Iranfar et al. (2026, Clin Transl Med) injected dual-AAV STRC into Strc-/- mice at postnatal ages P1 through P14-18. DPOAE and ABR measured 4 weeks post-injection.
| Injection age | OHC transduction | Hearing recovery |
|---|---|---|
| P1-P5 | ~60% | Full — WT-level ABR/DPOAE |
| P7-P9 | Declining | Partial |
| P14+ | Some transduction | Zero functional recovery |
Key numbers:
- At P1-P5: ~60% OHC co-transduction (both vectors), WT-level ABR and DPOAE thresholds restored.
- At P14+: 0% recovery. The window is hard-closed. Transduction can still occur, but stereocilia structure has reorganized beyond rescue.
Why the window closes
Two competing hypotheses:
- Structural rigidity: by P14, stereocilia bundles without horizontal top connectors have adopted an irreversible morphology. Providing STRC post-hoc cannot rebuild connections that never formed.
- Expression timing: STRC needs to be present during a critical maturation window for TM attachment crowns to form. Post-window delivery is too late for developmental scaffolding.
The distinction matters for human translation. If (1), there may be a longer window in humans because bundle maturation is slower. If (2), the window maps to gestational/early postnatal development and may already be closing in newborns.
No published data exists on STRC rescue at P30+, P60+, or adult in mice. This is the missing experiment.
Human translation
Direct P-day mapping does not apply. Human cochlear development runs on a different calendar.
| Parameter | Mouse | Human |
|---|---|---|
| Treatment window | P1-P5 | Prenatal–early postnatal (estimated) |
| Cochlea length | ~3.5 mm | ~35 mm |
| OHC count | ~3,300 | ~12,000 |
| Dual-AAV co-transduction | ~60% | 27.3% (Gamma-Poisson model, R=50%) |
| Hearing loss pattern | Stable, non-progressive | Stable, non-progressive |
The 10x cochlear scale means dual-AAV co-transduction drops dramatically in humans. Human cochlear development is largely complete by week 20 of gestation — earlier than many mouse comparisons imply.
What this means for Misha
DFNB16 is non-degenerative. OHCs survive. Stereocilia rootlets are anchored. The cells are structurally present but lack the protein that forms horizontal top connectors and TM attachment crowns. This is a better starting position than degenerative SNHL.
The argument for acting within the 2026-2031 window: by the time clinical-grade STRC gene therapy reaches Phase II (~2029-2032), Misha will be 8-11 years old. Two clocks run simultaneously: structural degradation of stereocilia and narrowing of the seronegative immune window. Both argue for earliest possible intervention.
The OTOF comparison is tempting but wrong. AK-OTOF restored hearing in an 11-year-old. But OTOF affects synaptic vesicle release — a chemical problem. STRC is structural. Different biology.
Key uncertainty
Whether the P5 cutoff in mice reflects structural plasticity that is already lost in Misha (age 4) is the single most important unknown. No data. The Tarchini 2021 finding that TM attachment crowns reformed even from full KO baseline (P1 injection) is the most encouraging data point — it shows TM retains structural capacity to embed stereocilia tips when STRC is provided. Whether that capacity persists in older mice or humans is untested.
Connections
[source]Iranfar 2026 — Dual AAV STRC (mouse) — primary mouse data[part-of]STRC Gene Therapy Landscape 2026 — therapeutic strategy context[see-also]Adult Treatment Window STRC — extended analysis of the adult window question[see-also]STRC Anti-AAV Immune Response Model — second clock: seronegative window[see-also]STRC Dual-Vector vs Single-Vector Transduction — why the 27.3% human co-transduction estimate matters[see-also]STRC Stereocilia Bundle Mechanics Model — OHC survival and structural integrity context[about]Misha